Latest Period
Q2 2026
Security Snapshot
Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (PHVS) Institutional Ownership
CUSIP: N69605108
13F Institutional Holders and Ownership History from Q1 2021 to Q2 2026
Institutions Reporting
124
Shares (Excl. Options)
64,484,527
Price
$34.58
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary shares, par value Euro 0.12 per share
- Symbol
- PHVS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 64,484,527
- Total 13F value
- $2,229,818,200
- Portfolio coverage rank
- 0.01%
- Share change
- +5,586,929
- Value change
- +$199,599,373
- Number of holders
- 124
- Shares outstanding
- 70,522,724
- SEC-reported price per share
- $33.65
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PHVS - Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share is tracked under CUSIP N69605108.
- 124 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 110 to 124 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,664,385,298 to $2,229,818,200.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 124 institutions filings for Q2 2026.
Security key
N69605108
Latest holder period
Q2 2026
13F holders
124
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
PHVS full holder history
Pharvaris N.V. SEC filings
Pharvaris N.V. company facts
Pharvaris N.V. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP N69605108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PHVS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | 7.6% | $185,392,957 | 5,359,727 | GENERAL ATLANTIC, L.P. | 30 Jun 2026 | |||
| VIKING GLOBAL INVESTORS LP | 5.6% | $103,206,008 | 3,653,310 | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 | |||
| LSP V Cooperatieve U.A. | 4.9% | $118,457,225 | 3,424,609 | LSP V Cooperatieve U.A. | 30 Jun 2026 | |||
| Venrock Healthcare Capital Partners III, L.P. | 3.8% | $51,436,214 | 2,047,620 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Fund, L.P. | 2.5% | -17% | $41,020,425 | -$5,670,300 | 1,640,817 | -12% | Bain Capital Life Sciences Fund, L.P. | 31 Dec 2025 |
As of 30 Jun 2026, 124 institutional investors reported holding 64,484,527 shares of Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (PHVS). This represents 91% of the company’s total 70,522,724 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 9.3% | 6,565,272 | +4.5% | 0.01% | $227,027,106 |
| GENERAL ATLANTIC, L.P. | 9.3% | 6,550,757 | -18% | 7.8% | $226,525,177 |
| Foresite Capital Management IV, LLC | 6.8% | 4,778,581 | 0% | 57% | $165,243,331 |
| venBio Partners LLC | 6.6% | 4,643,430 | +0.09% | 31% | $160,569,809 |
| VIKING GLOBAL INVESTORS LP | 5.2% | 3,653,310 | 0% | 0.36% | $126,331,460 |
| EQT Fund Management S.a r.l. | 4.9% | 3,424,609 | 0% | 14% | $118,422,979 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4.8% | 3,376,042 | +8% | 1.2% | $116,743,532 |
| Bain Capital Life Sciences Investors, LLC | 3.8% | 2,675,509 | 0% | 5.5% | $92,519,101 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.4% | 2,392,934 | +13% | 0.01% | $82,747,658 |
| Polar Capital Holdings Plc | 3.3% | 2,326,389 | +198% | 0.23% | $80,446,532 |
| Point72 Asset Management, L.P. | 2.3% | 1,641,200 | +63% | 0.09% | $56,752,696 |
| Commodore Capital LP | 2% | 1,425,000 | -26% | 2.9% | $49,276,500 |
| NOVO HOLDINGS A/S | 2% | 1,400,000 | -20% | 2.8% | $48,412,000 |
| Saturn V Capital Management LP | 1.9% | 1,314,122 | +9.4% | 6.5% | $45,442,339 |
| TCG Crossover Management, LLC | 1.4% | 1,008,229 | 0.84% | $34,864,559 | |
| Sofinnova Investments, Inc. | 1.2% | 881,299 | +7.7% | 1.6% | $30,475,319 |
| 5AM Venture Management, LLC | 1.1% | 797,600 | 0% | 9.6% | $27,581,008 |
| Seven Fleet Capital Management LP | 1.1% | 774,501 | +348% | 4.4% | $26,782,245 |
| BlackRock, Inc. | 1.1% | 771,454 | +1.9% | 0% | $26,676,879 |
| Cormorant Asset Management, LP | 1.1% | 750,000 | -25% | 1.3% | $25,935,000 |
| Soleus Capital Management, L.P. | 1% | 730,907 | +4.1% | 0.87% | $25,274,764 |
| Jones Hill Capital LP | 0.96% | 677,879 | +306% | 5% | $23,441,056 |
| Patient Square Capital LP | 0.95% | 671,209 | +36% | 3.6% | $23,210,407 |
| Foresite Capital Management V, LLC | 0.94% | 664,142 | +242% | 6.3% | $22,966,030 |
| Kynam Capital Management, LP | 0.94% | 661,795 | +3.3% | 1.3% | $22,884,871 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Latest
Q2 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 64,484,527 | $2,229,818,200 | +$199,599,373 | $34.58 | 124 |
| 2026 Q1 | 58,921,412 | $1,664,385,298 | -$6,360,608 | $28.25 | 110 |
| 2025 Q4 | 59,040,212 | $1,638,008,634 | +$19,048,600 | $27.75 | 107 |
| 2025 Q3 | 57,844,608 | $1,443,142,875 | +$236,461,176 | $24.95 | 83 |
| 2025 Q2 | 45,040,180 | $792,712,813 | +$1,806,103 | $17.60 | 60 |
| 2025 Q1 | 44,939,067 | $705,543,867 | +$4,132,739 | $15.70 | 52 |
| 2024 Q4 | 44,644,168 | $855,824,077 | -$7,190,155 | $19.17 | 54 |
| 2024 Q3 | 45,045,428 | $834,243,398 | +$34,119,580 | $18.52 | 51 |
| 2024 Q2 | 43,008,763 | $808,565,649 | +$10,680,383 | $18.80 | 36 |
| 2024 Q1 | 42,425,740 | $980,459,437 | +$36,728,417 | $23.11 | 35 |
| 2023 Q4 | 40,745,703 | $1,142,917,292 | +$327,949,428 | $28.05 | 36 |
| 2023 Q3 | 29,067,102 | $606,630,419 | +$4,468,799 | $20.87 | 21 |
| 2023 Q2 | 28,913,752 | $441,577,880 | +$109,619,000 | $15.14 | 21 |
| 2023 Q1 | 21,781,494 | $173,888,454 | +$3,756,313 | $8.06 | 21 |
| 2022 Q4 | 21,301,855 | $239,644,411 | -$1,830,525 | $11.25 | 25 |
| 2022 Q3 | 22,314,954 | $173,600,000 | -$317,120 | $7.67 | 21 |
| 2022 Q2 | 22,353,338 | $494,009,000 | +$14,911,660 | $22.10 | 20 |
| 2022 Q1 | 21,685,388 | $397,090,000 | +$838,867 | $18.14 | 22 |
| 2021 Q4 | 21,647,018 | $321,068,000 | -$1,695,268 | $14.39 | 22 |
| 2021 Q3 | 21,631,638 | $380,302,000 | -$6,827,497 | $17.73 | 25 |
| 2021 Q2 | 21,995,815 | $406,288,000 | -$1,442,853 | $18.62 | 28 |
| 2021 Q1 | 22,025,122 | $616,507,000 | +$616,507,000 | $27.99 | 33 |